IP Library Granted Patent US 11,351,347
Granted Patent B2
US 11,351,347 · App. 15/331,603 · Granted Jun 7, 2022

Vacuum-assisted drug delivery device and method

Inventors: David Myung (San Jose, CA); Edward E. Manche (Los Altos, CA); Donald J. Eaton (Los Altos, CA); Anthony J. Abbate (Santa Clara, CA)
Assignee: Vacu-Site Medical, Inc.
A61M37/00A61F9/0008A61F9/0017A61M1/00A61M5/14248A61M5/158A61M35/003A61M2037/0007A61M2210/0612
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,347
App. No.
15/331,603
Granted
Jun 7, 2022
Kind
B2
Abstract

This invention relates to a device and method for the vacuum-assisted delivery of drugs through an intact surface membrane of an organ.

Claims (16)

1. A method for delivering a drug into a tissue of a patient non-invasively for treating a disease or condition in the patient in need thereof, comprising:

placing a surface of a drug reservoir in contact with an epithelial or surface of the tissue to which the surface of the drug reservoir has been conformed such that an air-tight contact between the drug reservoir surface and the epithelial or surface of the tissue is formed and such that a fluid in the drug reservoir is placed in fluid communication through the surface of the drug reservoir with the epithelial or surface of the tissue; and

creating a vacuum within the drug reservoir without disrupting the tissue and to effect diffusion of the fluid in the drug reservoir through the epithelial or surface of the tissue and into the subsurface of the tissue.

2. The method of claim 1 , wherein the surface of the tissue is the epithelial surface.

3. The method of claim 2 , where the fluid comprises a substance that is capable of catalyzing the cross-linking of macromolecules in the tissue.

4. The method of claim 1 , wherein the fluid comprises an anti-microbial, an anti-inflammatory, an analgesic, antiseptic, or an anti-VEGF drug.

5. The method of claim 1 , wherein the delivery of a drug is for the treatment of uveitis, keratoconus, glaucoma, dry eye, diabetic macular edema, age-related macular degeneration, corneal infection or cytomegalovirus retinitis.

6. The method of claim 1 , wherein the vacuum is a pressure between 1 and 100 torr.

7. A method for delivering a drug into the skin of a patient for treating a disease or condition in the patient in need thereof, comprising:

placing a surface of a drug reservoir in contact with a skin surface to which the surface of the drug reservoir forms an air-tight contact between the drug reservoir surface and the skin surface and such that a fluid in the drug reservoir is placed in fluid communication through the surface of the drug reservoir with the skin surface; and

creating a vacuum within the drug reservoir without disrupting the skin and to effect diffusion of the fluid in the drug reservoir through the skin surface and into a subsurface of the skin.

8. The method of claim 7 , wherein the drug is delivered into a sebaceous gland.

9. The method of claim 8 , wherein the drug is delivered through epidermal, dermal, and/or subcutaneous layers of the skin.

10. The method of claim 7 , wherein the drug is delivered into a bloodstream.

11. The method of claim 7 , wherein the drug is delivered into a sweat gland.

12. The method of claim 7 , wherein a vacuum is used to increase extracellular space and/or pore sizes within the skin prior to drug diffusion into the skin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: VACUMED, LLC
To: VACU-SITE MEDICAL, INC.
Reel/Frame 049681/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2018
From: MYUNG, DAVID; MANCHE, EDWARD E; EATON, DONALD J; ABBATE, ANTHONY J
To: VACUMED, LLC.
Reel/Frame 046885/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: SEROS MEDICAL, LLC; DONALD J. EATON, CEO
To: MYUNG, DAVE; MANCHE, EDWARD E.; EATON, DONALD J.; ABBATE, ANTHONY J.
Reel/Frame 041768/0476 →
Continuity (5)
Continuation In Part 14694703 · Apr 23, 2015
Provisional Application 62244678 · Oct 21, 2015
Provisional Application 62138330 · Mar 25, 2015
Provisional Application 61983409 · Apr 23, 2014
Related Publication 20170035975A1 · Feb 9, 2017
Cited By (7)
US 1,116,103 US 1,120,314 US 12,274,865 US 12,649,031 US 12,691,227 US 12,734,300 US 12,741,098